Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Lowered to $113.00 at UBS Group

Jazz Pharmaceuticals (NASDAQ:JAZZFree Report) had its price objective reduced by UBS Group from $117.00 to $113.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a neutral rating on the specialty pharmaceutical company’s stock.

Several other research analysts have also issued reports on JAZZ. Barclays cut their price target on Jazz Pharmaceuticals from $230.00 to $200.00 and set an overweight rating on the stock in a report on Friday, May 3rd. Needham & Company LLC reduced their price target on shares of Jazz Pharmaceuticals from $222.00 to $210.00 and set a buy rating for the company in a research report on Thursday, June 20th. HC Wainwright restated a buy rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, May 3rd. Cantor Fitzgerald reiterated an overweight rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Finally, Stifel Nicolaus upped their target price on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a buy rating in a report on Friday, March 15th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $188.62.

View Our Latest Analysis on JAZZ

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $105.09 on Tuesday. The firm has a 50 day moving average of $108.80 and a 200-day moving average of $116.44. The company has a market cap of $6.63 billion, a price-to-earnings ratio of 21.67, a price-to-earnings-growth ratio of 1.64 and a beta of 0.58. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. Jazz Pharmaceuticals has a 52 week low of $103.01 and a 52 week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. The company had revenue of $901.98 million during the quarter, compared to analyst estimates of $938.99 million. On average, equities analysts forecast that Jazz Pharmaceuticals will post 15.35 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 5,000 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the completion of the transaction, the executive vice president now owns 36,629 shares in the company, valued at $4,016,369.85. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rise Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 2,255.6% in the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 203 shares during the period. GAMMA Investing LLC increased its position in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 116 shares during the last quarter. Cape Investment Advisory Inc. raised its stake in shares of Jazz Pharmaceuticals by 14,600.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after buying an additional 292 shares during the period. Assetmark Inc. lifted its position in shares of Jazz Pharmaceuticals by 37.1% during the 4th quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 119 shares during the last quarter. Finally, Headinvest LLC bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth $56,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

(Get Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Featured Articles

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.